Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
embecta has completed the acquisition of Owen Mumford, a medical devices business in the UK, for £100 million upfront cash. Owen Mumford is a privately held innovator and manufacturer of drug delivery technologies and medical devices, including the Aidaptus next generation auto-injector platform. embecta acquires Owen Mumford to expand diabetes care technology into broader healthcare medical supplies and to strengthen drug-delivery platforms for pharmaceutical partners serving chronic care patients in obesity, diabetes, autoimmune diseases, and anaphylaxis markets. The healthcare M&A platform acquisition is a public company acquisition by embecta and includes up to £50 million in performance-based payments tied to Aidaptus net sales over three years following closing.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026